These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27564103)
1. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103 [TBL] [Abstract][Full Text] [Related]
2. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499 [TBL] [Abstract][Full Text] [Related]
3. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773 [TBL] [Abstract][Full Text] [Related]
4. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193 [TBL] [Abstract][Full Text] [Related]
5. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033 [TBL] [Abstract][Full Text] [Related]
6. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. Mladenov R; Hristodorov D; Cremer C; Hein L; Kreutzer F; Stroisch T; Niesen J; Brehm H; Blume T; Brümmendorf TH; Jost E; Thepen T; Fischer R; Stockmeyer B; Barth S; Stein C Int J Cancer; 2015 Dec; 137(11):2729-38. PubMed ID: 26041304 [TBL] [Abstract][Full Text] [Related]
7. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363 [TBL] [Abstract][Full Text] [Related]
9. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy. Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313 [TBL] [Abstract][Full Text] [Related]
10. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627 [TBL] [Abstract][Full Text] [Related]
11. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64). Chen J; Zhou JH; Ball ED Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927 [TBL] [Abstract][Full Text] [Related]
13. CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells. Yong SB; Chung JY; Kim SS; Choi HS; Kim YH Biomaterials; 2020 Feb; 230():119651. PubMed ID: 31787334 [TBL] [Abstract][Full Text] [Related]
14. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006 [TBL] [Abstract][Full Text] [Related]
15. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. van Roon JA; van Vuuren AJ; Wijngaarden S; Jacobs KM; Bijlsma JW; Lafeber FP; Thepen T; van de Winkel JG Arthritis Rheum; 2003 May; 48(5):1229-38. PubMed ID: 12746896 [TBL] [Abstract][Full Text] [Related]
16. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759 [TBL] [Abstract][Full Text] [Related]
17. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation. Yong SB; Kim HJ; Kim JK; Chung JY; Kim YH Sci Rep; 2017 Feb; 7():42171. PubMed ID: 28169353 [TBL] [Abstract][Full Text] [Related]
18. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147 [TBL] [Abstract][Full Text] [Related]
19. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo. Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493 [TBL] [Abstract][Full Text] [Related]
20. Fcgamma receptor 1 (CD64), a target beyond cancer. Thepen T; Huhn M; Melmer G; Tur MK; Barth S Curr Pharm Des; 2009; 15(23):2712-8. PubMed ID: 19689341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]